HLA-B18 (B18) is an HLA-B serotype. The serotype identifies the more common HLA-B*18 gene products. [1] (For terminology help see: HLA-serotype tutorial) B*1801, the most common allele is at highest frequencies in Northern Italy and the Balkans, a peak frequency distribution it …

HLA-B and HLA-C alleles are also associated with type 1A diabetes independent of DR/DQ[17]. HLA-B18, B39, B44, C3, C8 and C16 are associated with type 1A diabetes and with age of onset after adjustment for linkage disequilibrium with DR/DQ[17].

May 31, 2016 · The only factor identified as a risk factor for liver fibrosis progression was the HLA-B18 allele (HLA-B18 pos 73.3% vs HLA-B18 neg 38.2%; P=0.011).

HLA-B18 pos patients more frequently had a higher and faster fibrosis progression rate (73.3%; 24 (IQR: 8-29) months) than HLA-B18 neg patients (38.2%; 34.5 (IQR: 14.7-51.2) months).

HLA-B18 Is risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients; HLA-A*31:01 and HLA-B*15:02 alleles confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions. There is a strong association between HLA-B*27 and ankylosing spondylitis patients in the Kurdistan Region of Iraq.

HLA-B*18:01 and HLA-DRB1*01, being unassociated with HLA-B*35, are genetic risk factors which seem to be population-independent SAT markers.

Oct 25, 2016 · We identified HLA-B18 as a factor associated with the progression of liver fibrosis (by at least one stage: HLA-B18 pos 81.1% vs HLA-B18 neg 38.9%; P =0.017). The median time-to-event was 24...

HLA-B18 is a well defined Bw6-associated serologic specificity. Up to now, four different sequences have been characterised in Caucasian populations (B*1801,3,4,5), and one in Orientals (B*1802). We report a new HLA-B18 subtype (B*1806) which was serologically detected in a Spanish Caucasian individ …

In this study, we have identified a novel HLA-B*1801-restricted CD8 + T cell epitope, NY-ESO-1 88–96 (LEFYLAMPF) and compared its direct- and cross-presentation to that of the reported NY-ESO-1 157–165 epitope restricted to HLA-A*0201.

In the present study we have taken advantage of the conservation and diabetogenicity of the B18-DR3 CEH, to identify disease-associated variability while controlling for LD with classical HLA risk variants.